Key result
Nesiritide therapy was not associated with worsening renal function compared to conventional therapy alone in patients admitted for decompensated heart failure (31.1% vs 31.9%; OR 0.8, 95% CI 0.4-1.6).
Why the study?
Does nesiritide increase the risk of worsening renal function in patients admitted for acute decompensated heart failure?
Population
206 patients admitted for acute decompensated heart failure
Comparison
Nesiritide added to conventional therapy vs Conventional therapy alone
Design
Cohort
Follow-up
index hospitalization
Authors
Loading...
Supports no increased renal risk with nesiritide in decompensated HF; hypothesis-generating and should not yet change practice.
Cohort (n=206)
Does nesiritide increase the risk of worsening renal function in patients admitted for acute decompensated heart failure?
Odds Ratio: 0.8 (95% CI 0.4–1.6)
Absolute Event Rate: 31.1% vs 31.9%
p-value: p=0.48
In a retrospective cohort of patients with acute decompensated heart failure, the addition of nesiritide to conventional therapy was not associated with an increased risk of worsening renal function.
Arora et al. (2007) conducted a cohort in Decompensated heart failure (n=206). Nesiritide along with conventional therapy vs. Conventional therapy alone was evaluated on Worsening renal function (rise in serum creatinine ≥0.3 mg/dl from baseline, with final creatinine >1.5 mg/dl) (OR 0.8, 95% CI 0.4-1.6, p=0.48). Nesiritide therapy was not associated with worsening renal function compared to conventional therapy alone in patients admitted for decompensated heart failure (31.1% vs 31.9%; OR 0.8, 95% CI 0.4-1.6).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: